Literature DB >> 12214326

The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats--in vitro and in vivo pharmacokinetic studies.

Hansjörg Wiegand1, Bernard Wirz, Alain Schweitzer, Gian P Camenisch, Maria I Rodriguez Perez, Gerhard Gross, Ralph Woessner, Rolf Voges, Per I Arvidsson, Jens Frackenpohl, Dieter Seebach.   

Abstract

IN VITRO STUDIES: In CaCo-2 cell monolayers the beta-nonapeptide H(beta-HAla-beta-HLys-beta-HPhe)(3)-OH.4HCl (1), (14)C-labeled on both C atoms of the CH(2)-CO moiety of the central beta-HPhe residue, showed a low intrinsic permeability (<1%) and is subject to a prominent efflux system. The beta-peptide (1) binds to human and rat plasma protein in vitro independent of the concentration of 1 and of the species (30-36% bound fraction at 50, 500, and 5000 ng/ml), and has only low affinity for the corresponding blood cells (less than 5% of compound 1 in blood cells). IN VIVO STUDIES: The in vivo pharmacokinetic characteristics after i.v. administration of 5 mg/kg (to male rats and to bile-duct-operated rats) were: (i) negligible in vivo biotransformation of 1 (in urine, plasma and feces unchanged 1 represented virtually the only compound-related molecule); (ii) rapid initial decline (0-8 h post dose) of levels of compound 1 in blood and plasma followed by a slower decline (8-96 h post dose); (iii) in non-operated animals after 96 h only 38% of the dose was excreted and after 168 h 49% of the dose was found remaining in the carcass; elimination through the intestine wall represented the major elimination pathway in non-operated animals while in bile-duct-cannulated animals biliary excretion was not found to contribute substantially to elimination (iv) quantitative whole-body autoradioluminography (QWBAL) investigations revealed that the kidney was by far the most important target organ of distribution; other tissues with high concentrations of compound-related radioactivity were cartilage, lymph nodes, and liver, whereas lowest levels were found in white fat and in the brain. After p.o. administration (10 mg/kg) negligible radioactivity was observed in the systemic circulation, indicating negligible absorption; essentially the entire oral dose was recovered unchanged in feces collected over a period of 96 h. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12214326     DOI: 10.1002/bdd.334

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

1.  Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer.

Authors:  Jiangeng Huang; Sai Praneeth R Bathena; Yazen Alnouti
Journal:  Drug Metab Pharmacokinet       Date:  2010-09-22       Impact factor: 3.614

2.  Development of a rotamer library for use in beta-peptide foldamer computational design.

Authors:  Scott J Shandler; Maxim V Shapovalov; Roland L Dunbrack; William F DeGrado
Journal:  J Am Chem Soc       Date:  2010-06-02       Impact factor: 15.419

3.  Crystal structure of a β-aminopeptidase from an Australian Burkholderia sp.

Authors:  Marietta John-White; Geoff J Dumsday; Priscilla Johanesen; Dena Lyras; Nyssa Drinkwater; Sheena McGowan
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-06-17       Impact factor: 1.056

4.  Inhibiting HIV fusion with a beta-peptide foldamer.

Authors:  Olen M Stephens; Sunghwan Kim; Brett D Welch; Michael E Hodsdon; Michael S Kay; Alanna Schepartz
Journal:  J Am Chem Soc       Date:  2005-09-28       Impact factor: 15.419

5.  Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors.

Authors:  Caroline Nunn; Magnus Rueping; Daniel Langenegger; Edi Schuepbach; Thierry Kimmerlin; Peter Micuch; Konstanze Hurth; Dieter Seebach; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-24       Impact factor: 3.000

6.  A novel beta-peptidyl aminopeptidase (BapA) from strain 3-2W4 cleaves peptide bonds of synthetic beta-tri- and beta-dipeptides.

Authors:  Birgit Geueke; Kenji Namoto; Dieter Seebach; Hans-Peter E Kohler
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

7.  Identification of a beta3-peptide HIV fusion inhibitor with improved potency in live cells.

Authors:  Arjel D Bautista; Olen M Stephens; Ligong Wang; Robert A Domaoal; Karen S Anderson; Alanna Schepartz
Journal:  Bioorg Med Chem Lett       Date:  2009-05-15       Impact factor: 2.823

Review 8.  Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.

Authors:  Marta Pelay-Gimeno; Adrian Glas; Oliver Koch; Tom N Grossmann
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-26       Impact factor: 15.336

Review 9.  Using Peptidomimetics and Constrained Peptides as Valuable Tools for Inhibiting Protein⁻Protein Interactions.

Authors:  Naomi S Robertson; David R Spring
Journal:  Molecules       Date:  2018-04-19       Impact factor: 4.411

10.  2-Phenyl-tetrahydropyrimidine-4(1H)-ones--cyclic benzaldehyde aminals as precursors for functionalised beta-amino acids.

Authors:  Markus Nahrwold; Arvydas Stoncius; Anna Penner; Beate Neumann; Hans-Georg Stammler; Norbert Sewald
Journal:  Beilstein J Org Chem       Date:  2009-09-14       Impact factor: 2.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.